Global Lung Cancer Therapeutics Market Is Expected To Reach Around USD 42.24 Billion By 2025

Zion Market Research has published a new report titled “Lung Cancer Therapeutics Market By Cancer Type (Non-Small Cell Lung Cancer and Small Cell Lung Cancer), By Treatment (Immunotherapy, Chemotherapy, Targeted Therapy, Radiation Therapy, and Others), By Drug Class (Antimetabolites, Alkylating Agents, Mitotic Inhibitors, EGFR Inhibitors, Multikinase Inhibitors, and Others), By End-User (Hospitals, Homecare, Specialty Clinics, and Others), and By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Internet, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025”. According to the report, the global lung cancer therapeutics market was valued USD 17.73 billion in 2018 and is expected to generate around USD 42.24 billion by 2025, growing at a CAGR of around 13.2% between 2019 and 2025.

Cancer is a disease caused by an uncontrolled division of abnormal cells in part of the body. These extra cells slowly gather together to form a tissue mass called a tumor. It reduces the lung’s ability to supply oxygen to the lymphatic system and bloodstream. Some leading lung cancer causes are prolonged exposure to asbestos, cigar, cigarette, tobacco intake, pipe-smoking, exposer to pollution, and harmful radiations. The main symptoms of lung cancer are wheezing, coughing, chest pain, appetite loss, shortness of breath, and weight loss.

Browse the full “Lung Cancer Therapeutics Market By Cancer Type (Non-Small Cell Lung Cancer and Small Cell Lung Cancer), By Treatment (Immunotherapy, Chemotherapy, Targeted Therapy, Radiation Therapy, and Others), By Drug Class (Antimetabolites, Alkylating Agents, Mitotic Inhibitors, EGFR Inhibitors, Multikinase Inhibitors, and Others), By End-User (Hospitals, Homecare, Specialty Clinics, and Others), and By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Internet, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025” Report at https://www.zionmarketresearch.com/report/lung-cancer-therapeutics-market

The lung cancer therapeutics market is predicted grow substantially, owing to the growing number of people suffering from lung cancer, rising number of smokers, increasing asbestos exposure, escalating demand for targeted therapies, presence of innovative and efficient drugs, and accelerating unhealthy lifestyle patterns. However, the high cost of drugs, the negative effects of radiation therapies and chemotherapies, and poor cancer diagnostic facilities may limit the lung cancer therapeutics market. 

The lung cancer therapeutics market is fragmented based on cancer type, treatment, drug class, end-user, and distribution channel. Based on cancer type, the lung cancer therapeutics market includes small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). More than 85% of the lung cancers are found to be NSCLC, which will drive this segment in the years ahead.

By treatment, the lung cancer therapeutics market includes immunotherapy, chemotherapy, targeted therapy, radiation therapy, and others.

Based on drug class, the market is divided into multikinase inhibitors, EGFR inhibitors, alkylating agents, mitotic inhibitors, antimetabolites, and others. Antimetabolites are expected to show the highest CAGR in the future.

Based on end-user, the lung cancer therapeutics market comprises hospitals, homecare, specialty clinics, and others. Homecare is expected to grow rapidly in the years ahead.

Based on the distribution channel, the market for lung cancer therapeutics is categorized into retail pharmacy, hospital pharmacy, internet, and others. Hospital pharmacy is predicted to show the highest CAGR in the future.

North America will dominate the lung cancer therapeutics market over the forecast timeframe, owing to the rising lung cancer occurrences and increasing geriatric population demanding therapeutics. Additionally, changing lifestyles and growing prevalence of smoking is leading to an escalating number of lung cancer incidences in North America. Europe is predicted to be the second-largest lung cancer therapeutics market, owing to the favorable government funding in the field of research, analysis, and development of innovative medication and technological growth related to cancer.

Some key players of the lung cancer therapeutics market are Pfizer, Hoffmann-La Roche, Eli Lilly and Company, Sanofi-Aventis, GlaxoSmithKline, Celgene Corporation, Boehringer Ingelheim, Agennix, AstraZeneca, and Merck & Co.

This report segments the global Lung cancer therapeutics market into:

Global Lung Cancer Therapeutics Market: By Cancer Type

• Non-Small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer (SCLC)

Global Lung Cancer Therapeutics Market: By Treatment

• Immunotherapy
• Chemotherapy
• Targeted Therapy
• Radiation Therapy
• Others

Global Lung Cancer Therapeutics Market: By Drug Class

• Antimetabolites
• Alkylating Agents
• Mitotic Inhibitors
• EGFR Inhibitors
• Multikinase Inhibitors
• Others

Global Lung Cancer Therapeutics Market: By End-User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Global Lung Cancer Therapeutics Market: By Distribution Channel

• Retail Pharmacy
• Hospital Pharmacy
• Internet
• Others

Global Lung Cancer Therapeutics Market: By Region

• North America
  • The U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• The Middle East and Africa

About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com